DOCSLIB.ORG

Recombinant Diphtheria Toxin Derivatives: Perspectives of Application S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recombinant Diphtheria Toxin Derivatives: Perspectives of Application S ISSN 10681620, Russian Journal of Bioorganic Chemistry, 2012, Vol. 38, No. 6, pp. 565–577. © Pleiades Publishing, Ltd., 2012. Original Russian Text © S.I. Romaniuk, D.V. Kolybo, S.V. Komisarenko, 2012, published in Bioorganicheskaya Khimiya, 2012, Vol. 38, No. 6, pp. 639–652. Recombinant Diphtheria Toxin Derivatives: Perspectives of Application S. I. Romaniuk1, D. V. Kolybo, and S. V. Komisarenko Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv Received October 12, 2011; in final form, November 25, 2011 Abstract—Diphtheria toxin (DT) is a unique bacterial protein which consists of three domains with various biological functions. Using genetic engineering for the creation of various recombinant constructions of DT with definite features, it is possible to create unique tools for cellular biology and toxins with efficient and selective action on certain populations of cells. The review highlights the structural and functional aspects of the DT molecule, its fragments and domains, as well as the major areas of application of its recombinant derivatives. In particular, the perspectives for practical use of recombinant DT derivatives are discussed for creating immunobiological preparations, cytotoxins, blockers of the heparinbinding epidermal growth fac torlike growth factor (HBEGF), protein constructions for direct delivery of substances into the cell, and also the possibility to use DT recombinant derivatives for therapy and prevention of a number of diseases. Keywords: diphtheria toxin, fragments and domains of diphtheria toxin, recombinant proteins, heparinbinding epidermal growth factorlike growth factor (HBEGF), vaccines, cytotoxins DOI: 10.1134/S106816201206012X 1 INTRODUCTION medicine, since they did not satisfy the thermostability requirements and the process to obtain them was not Diphtheria toxin (DT) is a globular protein that is standardized completely. classified to the family of the ABtype bacterial exo toxins [1]. It is the major factor of pathogenicity of the The development of genetic engendering tech Сorynebacterium diphtheriae, diphtheria causative niques made it possible to obtain recombinant diph agent [2]; nevertheless, the toxin is encoded in the theria toxoids with mutations in various enzymes that genome of a corynephage, which infects this bacte are currently more often used in both fundamental rium [3]. DT is the most toxic toxin among protein research and in medical practice (Fig. 1). The fast pace toxins in relation to sensitive cells in vitro (one mole of development in this area, and progress in the field of cule of this toxin is sufficient to kill a cell [4]), molecular biological techniques, make it urgent to although DT yields to the botulism and tetanus neuro estimate the prospects for the use of DT recombinant toxins in its influence on the organism [5]. The high derivatives in various areas of human activity. toxicity of DT opened perspectives on the use of its derivatives in medical practice and attracted the atten 1. Structure of the DT Molecule. Application tion of researchers to the study of the structure and of Recombinant Derivatives of the Toxin mechanism of action of this toxin. for Studying the Mechanism of Its Action When studying the antigenic features of DT, The DT is encoded by the nucleotide sequence of mutant forms of the toxin were found that exhibit no the tox gene (1683 bp) which is absolutely identical in cytotoxicity and were called CRM (from English— corynephages β [7], γ [8], and ω [9], which evidences crossreacting material) due to their ability of cross the high conservatism of this gene and the importance reactivity in a precipitation reaction with immune sera of all of the elements of the toxin molecule to fulfill its to DT [6]. Nevertheless, the chemically conjugated cytotoxic function. CRMbased chimeric proteins were not widely used in The DT polypeptide has a molecular weight of Abbreviations: DT is diphtheria toxin, CRM is crossreacting 58358 Da and consists of 560 amino acid residues, 25 material (mutant diphtheria toxoid is similar in its antigenic fea of which comprise the leader peptide [10]. Two disul tures to the diphtheria toxin), HBEGF is heparinbinding epi fide bonds are formed between cysteines at the posi dermal growth factorlike growth factor, IL is interleukin, and scFv is a singlechain fragment variable. tions 186–201 and 461–471 [11]. Figure 2 shows a 1 Corresponding author: phone: +38(044)2343354; fax: scheme of the DT molecular structure, which consists +38(044)2796365; [email protected]. of two fragments: the fragment A (from English– 565 566 ROMANIUK et al. Studying the functions of cell receptors Studying the mechanisms Studying the role of DT action of cells in biological processes Fundamental Areas for use for the recombinant DT analogues Vaccines Direct delivery (against of drugs, Applied diphtheria and vaccines, other etc into cells infections) HBEGF blockers Diagnostic (antitumor and test systems and antidiphtheria) immune therapeutic Cytotoxins for cancer, preparations virus, autoimmune, and other disease treatment Fig. 1. The areas of recombinant DT derivatives application. Active) (21164 Da) which presents the catalytic C of the eukaryotic translation elongation factor eEF2 domain, and the fragment B (from English–Binding) that results in protein synthesis arrest in the cell [14] (37194 Da) which consists of a transport Tdomain and cell death via apoptosis [15]. and a receptorbinding Rdomain [11]. Each of the Using mutant diphtheria toxoids, the hydrophobic three domains of DT performs a specific biological Cterminal fragment (482–535) of the Rdomain of function for cytotoxic action. The Cterminal DT was established to be responsible for interaction Rdomain (386–535) binds with a receptor on the sur with the receptor of the target cell [12] (Fig. 3). The face of the cell [12], the Tdomain (205–378) provides spacious structure of the Rdomain is formed by two the translocation of the Cdomain into the cytosol βsheets which lie close to one another: the fourfold [13], and the Nterminal Cdomain (1–193) catalyzes βsheet is formed by the RB2, RB3, RB5, and RB8 the reaction of NAD+dependent ADPribosylation folds and the fivefold βsheet by the RB4, RB6, RB7, RB9, and RB10 folds [11]. The formation of hydrogen bonds between the RB6 fold and both βsheets results in the formation of the βbarrel with a jellyrolllike A B topology which is found for many proteins which С R interact with carbohydrate residues. The 461–471 dis ulfide bond holds a loop of nine amino acid residues by СRT which the phosphatebinding Psite (456–458–460– 472–474) with unknown function is located [11]. The S SSSLys516 and Phe530 residues, and also possibly the T Tyr514, Val523, Asn524, and Lys526, play an essential role in receptor recognition and are located in the exposed region of the Rdomain [16]. The DT is activated via splitting the peptide bond Fig. 2. Scheme of DT domain structure. C is the catalytic domain, T is the transmembrane domain, R is the recep between the fragments A and B in the region 186–201 torbinding domain, A is fragment A, B is fragment B, and under the action of proteinases, e.g., furin [17] in the –S–S– is disulfide bonds. presence of disulfide bond reducers. The uptake of RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY Vol. 38 No. 6 2012 RECOMBINANT DIPHTHERIA TOXIN DERIVATIVES 567 Glu148 Tyr54 Active center His21 Tyr65 Thr23 Fragment Hairpin loop Т8/9 Lys516 482–535 Asp352 Glu349 Fig. 3. Structural elements of the DT molecule that are especially essential for catalytic, transport, and receptorbinding functions of the toxin. activated toxin complex with a cellular receptor by the fusion of early endosomes [24], and possibly to endosome with lower pH values (4.5–5.5) provides cause a delay in their maturation, which may be essen conformational rearrangements in the Tdomain [18], tial for the translocation process. which is a specialized pHdependent chaperone that Data on the participation of some cytosol proteins provides Cdomain translocation through the endo in the translocation of Cdomain have recently been some membrane into the cytosol [19]. obtained, e.g., vesicular transport proteins COPI, The Tdomain consists of nine helices organized which interact with Lys residues of the TH1 helix [25], into three layers. The first layer forms two long hydro actin [26], Hsp 90 chaperone, and thioredoxin reduc phobic Cterminal TH8 and TH9 helices; the second tase [27]. Nevertheless, a definite concept of the trans layer, three hydrophobic TH5–TH7 helices; and the location mechanism has not been formulated thus far, third, four TH1–TH4 helices with hydrophilic fea which makes it necessary and promising to further tures [11]. The construction of diphtheria toxoids study this process, including the application of recom which are able to bind with the receptor and exhibit binant DT derivatives. catalytic activity, but which would be unable to trans The Cdomain which carries out the NAD+ locate, e.g., the CRM503 [20], was useful for detecting dependent ADPribosylation of the eEF2 elongation the regions of the toxin molecule essential for translo factor consists of two βsheet subdomains, whose folds cation. Protonation of the Glu349 and Asp352 resi are oriented almost perpendicularly and form the core dues at low pH values (Fig. 3) leads to the TH8/9 hair of the domain. The first subdomain consists of the pin loop insertion into the membrane [21]. At a deep CB2, CB4, and CB8 folds which are surrounded by insertion, the TH5–TH7 helices are also inserted into the CH2, CH3, CH6, and CH7 helices. The second the membrane, and the TH5 helix, along with the TH8 subdomain consists of the CB1, CB3, CB5, CB6, and and TH9 helices, participates in pore formation. The CB7 folds which are surrounded by the CH1, CH4, TH6 and TH7 helices may form a “cork”, which par and CH5 helices. Four helices CL1–CL4 connect two tially blocks the transmembrane pore [22].
Load more

Recommended publications
  • Biological Toxins Fact Sheet
    Work with FACT SHEET Biological Toxins The University of Utah Institutional Biosafety Committee (IBC) reviews registrations for work with, possession of, use of, and transfer of acute biological toxins (mammalian LD50 <100 µg/kg body weight) or toxins that fall under the Federal Select Agent Guidelines, as well as the organisms, both natural and recombinant, which produce these toxins Toxins Requiring IBC Registration Laboratory Practices Guidelines for working with biological toxins can be found The following toxins require registration with the IBC. The list in Appendix I of the Biosafety in Microbiological and is not comprehensive. Any toxin with an LD50 greater than 100 µg/kg body weight, or on the select agent list requires Biomedical Laboratories registration. Principal investigators should confirm whether or (http://www.cdc.gov/biosafety/publications/bmbl5/i not the toxins they propose to work with require IBC ndex.htm). These are summarized below. registration by contacting the OEHS Biosafety Officer at [email protected] or 801-581-6590. Routine operations with dilute toxin solutions are Abrin conducted using Biosafety Level 2 (BSL2) practices and Aflatoxin these must be detailed in the IBC protocol and will be Bacillus anthracis edema factor verified during the inspection by OEHS staff prior to IBC Bacillus anthracis lethal toxin Botulinum neurotoxins approval. BSL2 Inspection checklists can be found here Brevetoxin (http://oehs.utah.edu/research-safety/biosafety/ Cholera toxin biosafety-laboratory-audits). All personnel working with Clostridium difficile toxin biological toxins or accessing a toxin laboratory must be Clostridium perfringens toxins Conotoxins trained in the theory and practice of the toxins to be used, Dendrotoxin (DTX) with special emphasis on the nature of the hazards Diacetoxyscirpenol (DAS) associated with laboratory operations and should be Diphtheria toxin familiar with the signs and symptoms of toxin exposure.
    [Show full text]
  • Targeted Neuronal Cell Ablation in the Drosophila Embryo: Pathfinding by Follower Growth Cones in the Absence of Pioneers
    Neuron, Vol. 14, 707-715, April, 1995, Copyright© 1995 by Cell Press Targeted Neuronal Cell Ablation in the Drosophila Embryo: Pathfinding by Follower Growth Cones in the Absence of Pioneers David M. Lin,* Vanessa J. Auld,*t reach their targets in the CNS (Wigglesworth, 1953). The and Corey S. Goodman ability of the initial axons to guide later growth cones has Howard Hughes Medical Institute led to the suggestion that pioneering growth cones might Division of Neurobiology be endowed with special pathfinding abilities. Do subse- Department of Molecular and Cell Biology quent growth cones possess the same pathfinding abili- Life Science Addition, Room 519 ties, or are they different from the pioneers? University of California, Berkeley Ablation experiments in a variety of organisms thus far Berkeley, California 94720 have provided a range of conflicting answers to this ques- tion. In the grasshopper embryo CNS, the G growth cone turns anteriorly along the P axons in the NP fascicle, a Summary pathway formed by the three descending P and the two ascending A axons. Although the A and P axons normally We developed a rapid method that uses diphtheria fasciculate and follow one another, either can pioneer the toxin, the flp recognition target sequences, and the complete pathway on its own. Furthermore, any one of GAL4-UAS activation system, to ablate specific neu- the P axons will suffice, since when any two of them are rons in the Drosophila embryo and to examine the con- ablated the remaining P pioneers the pathway. When the sequences in large numbers of embryos at many time three P axons are ablated, the G growth cone stalls, and points.
    [Show full text]
  • Diphtheria Toxin
    Duke University / Duke University Health System Policy on working with: Diphtheria Toxin I. Revision Page II. Background III. Risk Assessment IV. Policy Statement V. Emergency Information VI. Appendix I: EOHW Exposure/Injury Response Protocol VII. Appendix II: OESO SOP Template VIII. References This policy was first approved on December, 2018. Occupational and Environmental Safety Office (OESO) Employee Occupational Health and Wellness (EOHW) Page | 1 I. Revision Page Date Revision(s) / Comment(s) 12/06/2018 New policy document Page | 2 II. Background Diphtheria toxin (DT) is a biological toxin and is secreted by the bacterium Corynebacterium diphtheriae. DT is useful in biomedical research using mice because it can be used to selectively target and kill cells or organs without requiring surgery. Wild type mice do not have DT receptors, so they are relatively resistant to DT. The median lethal dose (LD50) for mice has been estimated at 1.6 mg/kg by subcutaneous injection compared to an estimated human LD50 of less than 100 ng/kg by IM injection. The gene for DT receptors can be inserted into a mouse genome so that the transgenic mice will express DT receptors only on specific cells. For example, a transgenic mouse engineered to express DT receptors only on hepatocytes can be injected with DT, which will only kill the hepatocytes, creating a nonsurgical mouse model without a functional liver. Diphtheria toxin doses used in transgenic mice range from 0.5 µg/kg to 50 µg/kg depending on the scientific goal (10 to 1000 ng for a 20-gram mouse).[Saito et al, 2001; Cha et al, 2003; Cerpa et al, 2014] A common dose is 100 ng per injection, sometimes administered in repeated doses to achieve a cumulative effect.
    [Show full text]
  • Diphtheria. In: Epidemiology and Prevention of Vaccine
    Diphtheria Anna M. Acosta, MD; Pedro L. Moro, MD, MPH; Susan Hariri, PhD; and Tejpratap S.P. Tiwari, MD Diphtheria is an acute, bacterial disease caused by toxin- producing strains of Corynebacterium diphtheriae. The name Diphtheria of the disease is derived from the Greek diphthera, meaning ● Described by Hippocrates in ‘leather hide.’ The disease was described in the 5th century 5th century BCE BCE by Hippocrates, and epidemics were described in the ● Epidemics described in 6th century AD by Aetius. The bacterium was first observed 6th century in diphtheritic membranes by Edwin Klebs in 1883 and cultivated by Friedrich Löffler in 1884. Beginning in the early ● Bacterium first observed in 1900s, prophylaxis was attempted with combinations of toxin 1883 and cultivated in 1884 and antitoxin. Diphtheria toxoid was developed in the early ● Diphtheria toxoid developed 7 1920s but was not widely used until the early 1930s. It was in 1920s incorporated with tetanus toxoid and pertussis vaccine and became routinely used in the 1940s. Corynebacterium diphtheria Corynebacterium diphtheriae ● Aerobic gram-positive bacillus C. diphtheriae is an aerobic, gram-positive bacillus. ● Toxin production occurs Toxin production (toxigenicity) occurs only when the when bacillus is infected bacillus is itself infected (lysogenized) by specific viruses by corynebacteriophages (corynebacteriophages) carrying the genetic information for carrying tox gene the toxin (tox gene). Diphtheria toxin causes the local and systemic manifestations of diphtheria. ● Four biotypes: gravis, intermedius, mitis, and belfanti C. diphtheriae has four biotypes: gravis, intermedius, mitis, ● All isolates should be tested and belfanti. All biotypes can become toxigenic and cause for toxigenicity severe disease.
    [Show full text]
  • Cold Sensing by Nav1.8-Positive and Nav1.8-Negative Sensory Neurons
    Cold sensing by NaV1.8-positive and NaV1.8-negative sensory neurons A. P. Luiza, D. I. MacDonalda, S. Santana-Varelaa, Q. Milleta, S. Sikandara, J. N. Wooda,1, and E. C. Emerya,1 aMolecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom Edited by Peter McNaughton, King’s College London, London, United Kingdom, and accepted by Editorial Board Member David E. Clapham January 8, 2019 (received for review August 23, 2018) The ability to detect environmental cold serves as an important define the distribution and identity of cold-sensitive DRG neurons, survival tool. The sodium channels NaV1.8 and NaV1.9, as well as in live mice, using in vivo imaging. the TRP channel Trpm8, have been shown to contribute to cold sensation in mice. Surprisingly, transcriptional profiling shows that Results NaV1.8/NaV1.9 and Trpm8 are expressed in nonoverlapping neuro- Distribution of DRG Sensory Neurons Responsive to Noxious Cold, in nal populations. Here we have used in vivo GCaMP3 imaging to Vivo. To identify cold-sensitive neurons in vivo, we used a pre- identify cold-sensing populations of sensory neurons in live mice. viously developed in vivo imaging technique to study the responses We find that ∼80% of neurons responsive to cold down to 1 °C do of individual DRG neurons in situ (8). Mice coexpressing Pirt- not express NaV1.8, and that the genetic deletion of NaV1.8 does GCaMP3 (which enables pan-DRG GCaMP3 expression), not affect the relative number, distribution, or maximal response NaV1.8 Cre, and a Cre-dependent reporter (tdTomato) were of cold-sensitive neurons.
    [Show full text]
  • Diphtheria Toxin Effects on Human Cells in Tissue Culture1
    [CANCER RESEARCH 36, 4590-4594, December 1976] Diphtheria Toxin Effects on Human Cells in Tissue Culture1 Barbara R. Venter2 and Nathan 0. Kaplan3 Departments of Biology (B. A. V.) and Chemistry (N. 0. K.), University of California, San Diego, La Jolla, California 92093 SUMMARY component that renders the hybrids retaining chromosome 5 much more sensitive to diphtheria toxin. HeLa calls exposed to a single sublethal concentration of Several reports have appeared in the recent literature diphtheria toxin were found to have diminished sensitivity exploring the possible use of diphtheria toxin as an anhineo when subsequently reaxposad to the toxin. Three calls plastic agent (2, 8). In 1974, lglewski and Rithenbeng (5) strains exhibiting toxin resistance were developed. In the reported that diphtheria toxin produced a greater inhibitory calls that had previously been exposed to toxin at 0.015 j.@g/ effect on protein synthesisof humanand mousetumor cells ml, 50% inhibition of protein synthesis required a toxin than on normal tissues from the same species. Their paper concentration of 0.3 pg/mI, which is more than 10 times expanded upon an earlier study by Buzzi and Maistrallo (1) that required in normal HeLa cells. in which it was reported that striking results could be ob There appears to be a threshold level of diphtheria toxin tamed with diphtheria toxin treatment of experimental hu action.Concentrationsof toxingreaterthan that required momsin Swiss mica. Papenheiman and Randall (9), in 1975, for 50% inhibition of protein synthesis (0.01 @g/ml)are while confirming that diphtheria toxin causes some tempo associated with cytotoxicity, whereas those below this con nary regression of Ehrlich ascihas tumors in mice, were less cantration may not be lethal.
    [Show full text]
  • Bio-Toxins-And-Venoms.Pdf
    Institutional Biosafety Committee Policy: Applies to: BIOSAFETY BEST PRACTICES FOR Vanderbilt University (VU) RESEARCH USE OF BIOLOGICAL Vanderbilt University Medical Center (MC) TOXINS & VENOMS This document applies to the use of biological toxins and venoms that are: 1. received in a premeasured quantity packaged in a septum vial that will not be opened prior to reconstitution with a vial adapter; and 2. meets one or more of the following criteria: toxin/venom presents a life-threatening or severe irreversible health effect risk in a single exposure incident scenario (i.e., acutely toxic); toxin/venom is included on the CDC/APHIS Select Agent List. Any toxin work that meets the two conditions above will require registration with, and approval by, the Institutional Biosafety Committee (IBC) as outlined below. Common examples of toxin use that meet the criteria above include: . tetrodotoxin used in cell culture or on animal protocols, . staphylococcal enterotoxin B (SEB) used for cell culture, and . administration of diphtheria toxin on animal protocols. NOTE: If work with acutely toxic materials is planned, but it requires manipulation of dry toxin, consult with VEHS Chemical & Laboratory Safety. Institutional Biosafety Committee Review & Approval for Possession and Use of Toxins In order to gain approval for this activity, the following actions must be completed. 1. The PI must complete and submit a Vanderbilt Biological Materials Registration (or amend an existing registration). 2. The PI must prepare and maintain a Toxin Safety Plan in the lab that includes: A copy of this document; Manufacturer’s safety data sheets (SDS) for the toxin(s) to be used; Inventory for each toxin which will allow the end user to quickly and clearly communicate how much toxin is on hand in storage.
    [Show full text]
  • Involvement of Nicotinamide Adenine Dinucleotide in the Action of Cholera Toxin in Vitro (Adenylate Cyclase/Erythrocyte) D
    Proc. Nat. Acad. Sci. USA Vol. 72, No. 6, pp. 2064-2068, June 1975 Involvement of Nicotinamide Adenine Dinucleotide in the Action of Cholera Toxin In Vitro (adenylate cyclase/erythrocyte) D. MICHAEL GILL Harvard University, Department of Biology, 16 Divinity Ave., Cambridge, Massachusetts 02138 Communicated by A. M. Pappenheimer, Jr., March 14, 1975 ABSTRACT NAD is a necessary cofactor for the activa- daltons) is needed for adenylate cyilase activation in a lysate. tion of adenylate cyclase [ATP pyrophosphate-lyase Gill and King concluded that, cholera toxin acts upon (cyclizing), EC 4.6.1.11 by cholera toxin. Lysates of certain whenR types of cell that hydrolyze their endogenous store of a whole cell, its peptide Al must penetrate at least as far as NAD after cell disruption respond poorly or not at all to the inner surface of the membrane, if not into the cytoplasm cholera toxin. Lysates of pigeon erythrocytes, which lack itself. They suggested that peptide Al might be an enzyme enzymes that degrade NAD, provide a convenient and re- that catalyzes some intracellular reaction resulting in the producible system for assaying the activity of cholera toxin in vitro and allow investigation of the mechanism modification of a component of the inner surface of the plasma of action of the toxin upon broken cells. membrane, where adenylate cyclase is located. Gill and King noticed that erythrocyte ghosts would not The protein exotoxin secreted by Vibrio cholerae increases the respond to cholera toxin once they had been separated from adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), the soluble erythrocyte cytoplasm.
    [Show full text]
  • Mechanism of Insertion of Diphtheria Toxin: Peptide Entry And
    Proc. Natl. Acad. Sci. USA Vol. 81, pp. 3341-3345, June 1984 Biochemistry Mechanism of insertion of diphtheria toxin: Peptide entry and pore size determinations (photoreactive probes/membrane penetration/permeability/liposomes/Sendai virus) LEORA SHALTIEL ZALMAN AND BERNADINE J. WISNIESKI* The Department of Microbiology and The Molecular Biology Institute, University of California, Los Angeles, CA 90024 Communicated by Everett C. Olson, February 21, 1984 ABSTRACT Diphtheria toxin (DTx) is an extremely po- formed cation-selective channels in planar lipid membranes tent inhibitor of protein synthesis. It is secreted as a linear and 18-A pores in liposomes (4, 7). In contrast, Donovan et polypeptide, which is cleaved to produce disulfide-linked A al. (8) found that native DTx forms anion-selective channels and B fragments. Fragment A, the inhibitor of protein synthe- under acidic conditions and concluded these pores were too sis, requires fragment B, the recognition subunit, for entry small (5 A) to allow A to cross the membrane. While the into intact cells. Fragment B has been proposed to form a calculated channel size has been questioned, to our knowl- transmembrane channel through which A gains access to the edge no other pore size determinations have been performed cytosol. If it were demonstrated that the B subunit had an ex- with native DTx. clusive association with membrane lipid acyl chains, this might Because direct information about the nature of toxin- indicate that A is secluded in a proteinaceous B channel. How- membrane interactions is critical to solving the entry path- ever, our results from intramembranous photolabeling studies way, we used a photoreactive glycolipid probe (9, 10) to as- show that both subunits of DTx enter the hydrocarbon domain certain which of the two domains of the toxin penetrates the of the bilayer.
    [Show full text]
  • Structural Basis for Lack of Toxicity of the Diphtheria Toxin Mutant CRM197
    Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197 Enrico Malitoa,b, Badry Bursulayaa, Connie Chena,c, Paola Lo Surdob, Monica Picchiantib,d, Enrico Balduccie, Marco Biancuccib,f, Ansgar Brocka, Francesco Bertib, Matthew James Bottomleyb, Mikkel Nissumb, Paolo Costantinob, Rino Rappuolib,1, and Glen Spraggona,1 aGenomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121; bNovartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy; cJoint Center for Structural Genomics, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121; dDepartment of Evolutionary Biology, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy; eSchool of Biosciences and Biotechnologies, University of Camerino, via Gentile III da Varano, 62032 Camerino, Italy; and fDepartment of Chemistry, University of Siena, Via A. De Gasperi 2, 53100 Siena, Italy Contributed by Rino Rappuoli, February 4, 2012 (sent for review January 7, 2012) CRM197 is an enzymatically inactive and nontoxic form of tetravalent conjugate vaccine against serogroups A-C-W135-Y diphtheria toxin that contains a single amino acid substitution of Neisseria meningitidis, Menjugate® and Meningitec® (against (G52E). Being naturally nontoxic, CRM197 is an ideal carrier protein serotype C of N. meningitidis), Vaxem-Hib® and HibTITER® for conjugate vaccines against encapsulated bacteria and is (against Haemophilus influenzae type B, Hib), and the multivalent currently used to vaccinate children globally against Haemophilus pneumococcal conjugate Prevnar™ (12). influenzae, pneumococcus, and meningococcus. To understand the The widespread use of diphtheria toxoid and CRM197 has molecular basis for lack of toxicity in CRM197, we determined the prompted many investigations of DT and related proteins.
    [Show full text]
  • Human Antibodies Neutralizing Diphtheria Toxin in Vitro and in Vivo
    www.nature.com/scientificreports OPEN Human antibodies neutralizing diphtheria toxin in vitro and in vivo Esther Veronika Wenzel1, Margarita Bosnak1, Robert Tierney2, Maren Schubert1, Jefrey Brown3, Stefan Dübel 1, Androulla Efstratiou4, Dorothea Sesardic2, Paul Stickings2,5 & Michael Hust 1,5* Diphtheria is an infectious disease caused by Corynebacterium diphtheriae. The bacterium primarily infects the throat and upper airways and the produced diphtheria toxin (DT), which binds to the elongation factor 2 and blocks protein synthesis, can spread through the bloodstream and afect organs, such as the heart and kidneys. For more than 125 years, the therapy against diphtheria has been based on polyclonal horse sera directed against DT (diphtheria antitoxin; DAT). Animal sera have many disadvantages including serum sickness, batch-to-batch variation in quality and the use of animals for production. In this work, 400 human recombinant antibodies were generated against DT from two diferent phage display panning strategies using a human immune library. A panning in microtiter plates resulted in 22 unique in vitro neutralizing antibodies and a panning in solution combined with a functional neutralization screening resulted in 268 in vitro neutralizing antibodies. 61 unique antibodies were further characterized as scFv-Fc with 35 produced as fully human IgG1. The best in vitro neutralizing antibody showed an estimated relative potency of 454 IU/mg and minimal efective dose 50% (MED50%) of 3.0 pM at a constant amount of DT (4x minimal cytopathic dose) in the IgG format. The targeted domains of the 35 antibodies were analyzed by immunoblot and by epitope mapping using phage display. All three DT domains (enzymatic domain, translocation domain and receptor binding domain) are targets for neutralizing antibodies.
    [Show full text]
  • Subunit S1 of Pertussis Toxin: Mapping of the Regions Essential for ADP
    Proc. NatI. Acad. Sci. USA Vol. 85, pp. 7521-7525, October 1988 Biochemistry Subunit S1 of pertussis toxin: Mapping of the regions essential for ADP-ribosyltransferase activity (erts toxin/ADP-rlbosylatin/subunlt Sl/site-directed mutagenesis) MARIAGRAZIA PIZZA, ANTONELLA BARTOLONI, ANNA PRUGNOLA, SERGIO SILVESTRI, AND RINo RAPPUOLI Sclavo Research Center, Via Fiorentina 1, 53100 Siena, Italy Communicated by A. M. Pappenheimer, July 11, 1988 (receivedfor review April 8, 1988) ABSTRACT The toxicity of pertussis toxin is mediated by related, nontoxic molecules that can be used as vaccines (20- the ADP-ribosyltransferase activity of subunit S1. To under- 22). stand the structure-function relationship of'subunit Si and For diphtheria and Pseudomonas toxins, a series of stud- guide the construction of nontoxic molecules suitable for ies, which include nitrosoguanidine mutagenesis ofthe genes vaccines, we constructed and expressed in Escherichia coli a (23), characterization of the mutant genes (5) and their series of amino-terminal and carboxyl-terminal deletion mu- products (24-26), photoaffinity labeling of the toxins with tants as well as a number of molecules containing amino acid NAD (27, 28), site-directed mutagenesis (29, 30), and crys- substitutions. The shortest peptide still retaining enzymatic tallographic structure of the Pseudomonas exotoxin A (31) activity contains amino-acids 2-179. Within this region we have led to the identification of amino acids essential to the identified three mutants in which amino acid substitutions enzymatic activity of the proteins. For example, Glu-148 of abolish the enzymatic activity. Mutation of amino acids 8 and diphtheria toxin and Glu-553 of Pseudomonas -exotoxin A, 9 or.50 and 53, located within the region of the S1 subunit of located within the catalytic site of the two enzymes, cannot pertussis toxin homologous to cholera toxin, causes loss of be replaced even with an aspartic acid without abolishing enzymatic activity.
    [Show full text]